Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 15/460,147, filed Mar 15, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,259,865 | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | ||
| US 11,084,870 | Anti-Pneumococcal Hyperimmune Globulin for the Treatment and Prevention of Pneumococcal Infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | ||
| US 12,612,450 | Anti-Pneumococcal Hyperimmune Globulin for the Treatment and Prevention of Pneumococcal Infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence | ||
| US 11,897,943 | Anti-Pneumococcal Hyperimmune Globulin for the Treatment and Prevention of Pneumococcal Infection In force · High confidence | Adma Biomanufacturing, LLC | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.